Telisotuzumab vedotin (ABBV-399)

Telisotuzumab vedotin (ABBV-399) is an antibody drug conjugate (ADC) targeting cMet that is being investigated to treat non-small cell lung cancer.

Type of Molecule

Biologic

Target

cMet

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Non-Small Cell Lung Cancer n/a
Phase 2